CLARITY-NJ: Anti-Amyloid Therapy in Early Alzheimer's Disease

A randomized, placebo-controlled study of a monthly anti-amyloid monoclonal antibody infusion in participants with mild cognitive impairment or mild dementia due to Alzheimer's.

Key eligibility criteria

• Adults 60–85 years
• MMSE score 22–30
• Confirmed amyloid pathology (PET/CSF)
• Study partner available

Additional criteria apply. A full eligibility review is completed by our coordinators during pre-screening — you may still qualify even if you're unsure about a criterion.